

## RESEARCH ARTICLE

# Psychosocial well-being of long-term survivors of pediatric head–neck rhabdomyosarcoma

Bas Vaarwerk<sup>1,2</sup>  | Reineke A. Schoot<sup>1</sup>  | Heleen Maurice-Stam<sup>3</sup>  |  
Olga Slater<sup>4</sup> | Benjamin Hartley<sup>5</sup> | Peerooz Saeed<sup>6</sup> | Eva Gajdosova<sup>7</sup> | Michiel W. van  
den Brekel<sup>8,9</sup> | Alfons J.M. Balm<sup>8,9</sup> | Marinka L.F. Hol<sup>8</sup> | Stefanie van Jaarsveld<sup>1</sup> |  
Leontien C.M. Kremer<sup>1,2</sup> | Cecile M. Ronckers<sup>1,2</sup> | Henry C. Mandeville<sup>10</sup> |  
Bradley R. Pieters<sup>11</sup> | Mark N. Gaze<sup>12</sup>  | Raquel Davila Fajardo<sup>13</sup>  |  
Simon D. Strackee<sup>14</sup> | David Dunaway<sup>15</sup> | Ludi E. Smeele<sup>8,9</sup> | Julia C. Chisholm<sup>16</sup>  |  
Huib N. Caron<sup>1</sup> | Martha A. Grootenhuys<sup>2,3</sup> | Johannes H. M. Merks<sup>1,2</sup>

<sup>1</sup>Department of Paediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

<sup>2</sup>Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

<sup>3</sup>Paediatric Psychosocial Department, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

<sup>4</sup>Department of Paediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

<sup>5</sup>Department of Otorhinolaryngology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

<sup>6</sup>Orbital Centre, Department of Ophthalmology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

<sup>7</sup>Department of Ophthalmology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

<sup>8</sup>Department of Oral and Maxillofacial surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

<sup>9</sup>Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands

<sup>10</sup>Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

<sup>11</sup>Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

<sup>12</sup>Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

<sup>13</sup>Department of Radiation Oncology, UMC Utrecht Cancer Center, Utrecht, The Netherlands

<sup>14</sup>Department of Plastic, Reconstructive and Hand Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

<sup>15</sup>Craniofacial Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

<sup>16</sup>Children and Young People's Department, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

## Correspondence

Bas Vaarwerk, Department of Paediatric Oncology, Emma Children's Hospital/Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.  
Email: b.vaarwerk@amc.nl

## Funding information

Stichting Kinderen Kankervrij, Grant/Award Number: Grant number 175

## Abstract

**Background:** Head and neck rhabdomyosarcoma (HNRMS) survivors are at risk to develop adverse events (AEs). The impact of these AEs on psychosocial well-being is unclear. We aimed to assess psychosocial well-being of HNRMS survivors and examine whether psychosocial outcomes were associated with burden of therapy.

**Procedure:** Sixty-five HNRMS survivors (median follow-up: 11.5 years), treated in the Netherlands and the United Kingdom between 1990 and 2010 and alive  $\geq 2$  years after treatment visited the outpatient multidisciplinary follow-up clinic once, in which AEs were scored based on a

Abbreviations: AMORE treatment, Ablative surgery, MOuld technique after loading brachytherapy, and surgical REconstruction; CTC AE, Common Terminology Criteria for Adverse Events; EKZ-AMC, Emma Children's Hospital-Academic Medical Centre; GOSH, Great Ormond Street Hospital; HNRMS, head–neck rhabdomyosarcoma; HRQoL, health-related quality of life; NL, The Netherlands; PedsQL, Pediatric Quality of Life Inventory; RMH, The Royal Marsden Hospital; SWA, Satisfaction with appearances; UK, The United Kingdom; YQOL-FD, Youth Quality of Life Instrument—Facial Differences Module

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2018 The Authors. *Pediatric Blood & Cancer* Published by Wiley Periodicals, Inc.

predefined list according to the Common Terminology Criteria for Adverse Events. Survivors were asked to complete questionnaires on health-related quality of life (HRQoL; PedsQL and YQOL-FD), self-perception (KIDSCREEN), and satisfaction with appearances (SWA). HRQoL and self-perception scores were compared with reference values, and the correlation between physician-assessed AEs and psychosocial well-being was assessed.

**Results:** HNRMS survivors showed significantly lower scores on PedsQL school/work domain ( $P \leq 0.01$ ,  $P = 0.02$ , respectively), YQOL-FD domains negative self-image and positive consequences ( $P \leq 0.01$ ,  $P = 0.04$ , respectively) compared with norm data; scores on negative consequences domain were significantly higher ( $P = 0.03$ ). Over 50% of survivors negatively rated their appearances on three or more items. Burden of AEs was not associated with generic HRQoL and self-perception scores, but was associated with disease-specific QoL (YQOL-FD).

**Conclusion:** In general, HRQoL in HNRMS survivors was comparable to reference groups; however, survivors did report disease-specific consequences. We therefore recommend including specific questionnaires related to difficulties with facial appearance in a systematic monitoring program to determine the necessity for tailored care.

#### KEYWORDS

brachytherapy, Head and neck, pediatric oncology, psychosocial well-being, quality of life, radiotherapy, rhabdomyosarcoma

## 1 | INTRODUCTION

Pediatric rhabdomyosarcoma (RMS) accounts for 3% to 5% of all pediatric malignancies, and 40% of the cases arise in the head and neck area (HNRMS).<sup>1</sup> Overall survival for patients with localized RMS has increased to around 80% nowadays,<sup>2,3</sup> and the treatment for HNRMS usually consists of chemotherapy followed by local therapy. Microscopically free surgical margins are often difficult to achieve in the head and neck area; therefore, external beam radiotherapy is often the therapy of choice.

RMS generally occurs in young children, and radiotherapy at young age leads to abnormal growth and function of musculoskeletal tissues; therefore, many HNRMS survivors suffer from facial disfigurements (incidence rate, 35–77%).<sup>4–6</sup> Furthermore, other adverse events, such as growth hormone deficiency and cataract, are frequently reported.<sup>4–7</sup> The impact of these adverse events on psychosocial well-being is unclear. Multiple studies showed that, in general, health-related quality of life (HRQoL) in survivors of childhood cancer is comparable with normative values of healthy individuals; however, specific subgroups are at risk for impaired psychosocial well-being.<sup>8–11</sup> Identifying these subgroups at risk is important to develop adequate interventions to improve psychosocial well-being. Kinahan et al showed that in childhood cancer survivors, facial disfigurement negatively affected general health, mental health, and emotional well-being.<sup>12</sup> Previous studies also showed that HRQoL in children with facial deformities, such as cleft lip patients, is impaired.<sup>13,14</sup>

Therefore, psychosocial well-being of HNRMS survivors needs proper attention. Schoot et al previously showed that HRQoL among HNRMS survivors was comparable with normative values.<sup>6</sup> However, this study only described rather general HRQoL measurements. A more comprehensive understanding of the psychosocial well-being of HNRMS survivors is lacking.

In this study, psychosocial well-being was assessed by measuring HRQoL, self-perception, and satisfaction with appearances, in HNRMS survivors treated in three large pediatric oncology centers (Great Ormond Street Hospital [GOSH], London, The Royal Marsden Hospital [RMH], Sutton and Emma Children's Hospital-Academic Medical Centre [EKZ-AMC], Amsterdam). Furthermore, we examined whether physician-assessed adverse events were associated with psychosocial well-being.

## 2 | METHODS

### 2.1 | HNRMS survivors

All patients (aged 0–18 years) treated for HNRMS in GOSH, RMH, or EKZ-AMC, between 1990 and 2010 and alive  $\geq 2$  years after end of therapy were invited to the outpatient multidisciplinary clinic ( $n = 113$ ).

In this cross-sectional study, all survivors were evaluated once at the outpatient multidisciplinary clinics to evaluate the occurrence of adverse events.<sup>6</sup> Survivors  $\geq 8$  years of age were asked to complete questionnaires regarding their psychosocial well-being. Written informed consent was obtained from all survivors ( $> 12$  years) and their guardians treated in GOSH/RMH. For Amsterdam, the local institutional review board decided that the Act on Medical Research Involving Human Subjects did not apply, because data were collected during a regular follow-up clinic.

### 2.2 | Rhabdomyosarcoma treatment

Treatment details for this cohort have been described previously<sup>6</sup>; in general, all patients received multidrug chemotherapy and decisions on local therapy were made after two or three courses of

chemotherapy. If local therapy was indicated, the patients from the United Kingdom (UK) received external beam radiotherapy and the EKZ-AMC patients received AMORE (Ablative surgery, MOuld technique after loading brachytherapy, and surgical REconstruction) treatment if feasible and otherwise external beam radiotherapy.<sup>6,7,15–17</sup> AMORE treatment was considered feasible if a macroscopic radical resection and adequate mould placement seemed possible.

## 2.3 | Instruments

HNRMS survivors were asked to complete the *Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales*, self-perception domain of the *KIDSCREEN*, *Youth Quality of Life Instrument—Facial Differences Module (YQOL-FD)*, and the *Satisfaction with appearances (SWA)* questionnaire. The questionnaires are described in detail below. All HNRMS survivors were asked to complete respective questionnaires, unless explicit age groups are specified below.

## 2.4 | PedsQL

This questionnaire consists of 23 items assessing HRQoL on four subscales: physical functioning, emotional functioning, social functioning, and school/work functioning.<sup>18</sup> Each item states a problem, for example “I have trouble keeping up with school/work” or “I have trouble sleeping.” Each item was scored on a five-point Likert scale. Total score (all subscales) and psychosocial health (emotional, social, and school/work) were calculated by summing up scores of the corresponding subscales. Scores ranged 0 to 100, with higher scores indicating better HRQoL. We used weighted reference data, adjusted for sex, for Dutch (NL) survivors and for survivors < 18 years from the United Kingdom.<sup>19–21</sup> We used NL  $\geq 18$  years sex-adjusted reference data for UK survivors  $\geq 18$  years because no UK reference data were available for adults. We considered this legitimate because reference data for UK and Dutch children aged 11 to 18 years were comparable, and we assumed that reference data in  $\geq 18$  years old would also be comparable. Cronbach's alphas for both NL and UK survivors were moderate to good ( $\alpha$ : 0.73–0.96).

## 3 | KIDSCREEN

The KIDSCREEN self-perception domain consists of five items, for example, “have you been happy with the way you are?” Each item was scored on a five-point Likert scale. Raw domain scores were transformed into T-values, with a mean of 50 and standard deviation of 10 in the reference population. Higher scores indicate better HRQoL. We used age- and sex-adjusted country-specific reference values.<sup>22</sup> Cronbach's alphas for both NL and UK survivors were moderate to good ( $\alpha$ : 0.77–0.88).

### 3.1 | YQOL-FD

The YQOL-FD questionnaire, completed by survivors aged 11 to 18 years, consisted of 30 items assessing quality of life across five domains: stigma, negative self-image, positive consequences, nega-

tive consequences, and coping. The instrument is focused on the impact of living with a facial difference, and each item addresses a specific concern, for example, “people stare at me because of how my face looks.” Domain scores ranged from 0 to 100. Higher scores on the domains coping and positive consequences indicate *higher* quality of life. Higher scores on the domains negative consequences, negative self-image, and stigma indicate *lower* quality of life. No reference data were available for the YQOL-FD; one study reported data for 307 patients with congenital or acquired facial deformities, in which patients were grouped as mild, moderate, or marked based on self-rated facial deformities.<sup>23</sup> The scores obtained from patients with mild facial deformities ( $n = 250$ ) served as norm data for the functioning of HNRMS survivors. Cronbach's alphas for negative self-image, positive-consequences, negative-consequences, and stigma domain were moderate to good ( $\alpha$ : 0.66–0.96). Cronbach's alpha for the coping domain was 0.03 for NL survivors, and we decided to exclude this domain from further analyses.

### 3.2 | SWA

The SWA, developed by the Psychology Special Interest Group of the Craniofacial Society of Great Britain and Ireland, consists of 18 items (score range, 0–10), with higher scores indicating higher satisfaction with appearance. Each item assesses patients' satisfaction with a specific aspect of the way they look and function in society, for example, “How do you feel about the way you look?” We considered item scores less than 6 as negative. Two items, wearing a hearing aid and braces, were not used in the present study, because the number of survivors with hearing aids or braces was limited. A total mean score was calculated; missing data were imputed by mean scores on the individual item (max two items were imputed). So far, no reference data were published for the SWA. Cronbach's alphas for both NL and UK survivors were good ( $\alpha$ : 0.85–0.91).


### 3.3 | CTCAE

Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAEv4.0, available at <http://evs.nci.nih.gov/ftp1/CTCAE/About.html>). We used a selection of predefined adverse events as reported previously.<sup>6</sup> For each survivor, we assessed the total number of adverse events, any grade 3/4 adverse event, and total burden of adverse events by using a burden score adapted from Geenen et al.<sup>24</sup>

### 3.4 | Statistical analyses

Data were analyzed with SPSS version 23.0. Differences between participants and nonparticipants with respect to sex, tumor site and side, histology, treatment protocol, and radiotherapy were analyzed by Fisher exact tests, and difference in age at diagnosis was assessed by the Mann–Whitney test.

One-sample *t* tests were conducted to analyze whether HNRMS survivors' scores on PedsQL, KIDSCREEN, and YQOL-FD differed from reference values.



**FIGURE 1** Flow diagram: long-term survivors of HNRMS. <sup>a</sup>Patient developed recurrence after follow-up evaluation and did not fill out questionnaire

The SWA was analyzed descriptively. Mean, standard deviation, and the proportion of negative scores were calculated for each individual item and for the mean item score.

If appropriate, effect sizes were calculated by dividing differences in mean scores between the HNRMS survivors and reference values by the standard deviation of the reference group. Effect sizes of 0.2 were considered small, 0.5 medium, and 0.8 large.<sup>25</sup>

Pearson product-moment correlation coefficients were calculated to investigate whether adverse events (defined with CTC AE) were associated with psychosocial outcomes. We considered correlation coefficients of 0.1 as small, 0.3 as medium, and 0.5 as large.<sup>25</sup>

## 4 | RESULTS

### 4.1 | Survivors

In total, 80 survivors attended the follow-up clinic; 65 individuals (81.3%) also completed the questionnaires (Figure 1). The 15 nonparticipating survivors did not differ significantly from participating survivors with respect to demographic and medical variables (Supporting Information Table S1). Median age at time of questionnaire completion was 19.6 years (range, 8.6–35.7 years) for NL survivors and 16.0 years (range, 8.5–27.9 years) for UK survivors. Survivors' characteristics are further described in Table 1.

### 4.2 | Health-related quality of life (PedsQL)

In general, subdomain-specific HRQoL of HNRMS survivors did not differ significantly from weighted reference values, except for the

**TABLE 1** Characteristics ( $n = 65$ ) of HNRMS survivors

|                          |                | Netherlands<br>N = 36 | United Kingdom<br>N = 29 |
|--------------------------|----------------|-----------------------|--------------------------|
| Age at diagnosis (years) | Median (range) | 6.4 (0.5–13.4)        | 5.1 (1.0–11.9)           |
| Attained age (years)     | Median (range) | 19.6 (8.6–35.7)       | 16.0 (8.5–27.9)          |
| Follow-up (years)        | Median (IQR)   | 11.5 (8.5–18.0)       | 10.9 (6.0–18.5)          |
| Sex, $n$ (%)             | Male           | 20 (56%)              | 22 (76%)                 |
|                          | Female         | 16 (44%)              | 7 (24%)                  |
| Histology, $n$ (%)       | ERMS           | 32 (89%)              | 21 (72%)                 |
|                          | ARMS           | 4 (11%)               | 4 (14%)                  |
|                          | RMS NOS        |                       | 4 (14%)                  |
| Primary site, $n$ (%)    | PM             | 15 (42%)              | 15 (52%)                 |
|                          | ORB            | 13 (36%)              | 9 (31%)                  |
|                          | ORB&PM         | 2 (6%)                | 2 (7%)                   |
|                          | HNNPM          | 6 (17%)               | 3 (10%)                  |
| Side                     | Left           | 18 (50%)              | 10 (34%)                 |
|                          | Right          | 13 (36%)              | 17 (59%)                 |
|                          | Midline        | 5 (14%)               | 2 (7%)                   |
| Treatment protocol       | MMT 89         | 11 (31%)              | 9 (31%)                  |
|                          | MMT 95         | 19 (53%)              | 13 (45%)                 |
|                          | MMT 98         | 0                     | 1 (3%)                   |
|                          | RMS 2005       | 4 (11%)               | 6 (21%)                  |
|                          | Other          | 2 (6%)                | 0                        |
| Initial local Tx         | No RT          | 2 (6%)                | 2 (7%)                   |
|                          | AMORE          | 22 (61%)              | 0                        |
|                          | EBRT           | 12 (33%)              | 27 (93%)                 |
| Number of RT Tx          | 0              | 2 (6%)                | 2 (7%)                   |
|                          | 1              | 27 (75%)              | 27 (93%)                 |
|                          | 2              | 5 (14%)               | 0                        |
|                          | 3              | 2 (6%)                | 0                        |

Abbreviations: AMORE, Ablative surgery MOuld brachytherapy and REconstruction; ARMS, alveolar rhabdomyosarcoma; EBRT, external beam radiotherapy; ERMS, embryonal rhabdomyosarcoma; HNNPM, Head and neck nonparameningeal; IQR, interquartile range; MMT, consecutive study of International Society of Paediatric Oncology Malignant Mesenchymal Tumour group; ORB&PM, orbital with parameningeal extension; ORB, orbital; PM, parameningeal; RMS 2005, European *paediatric* Soft-Tissue Sarcoma group RMS 2005 protocol; RMS NOS, rhabdomyosarcoma not otherwise specified; RT, radiotherapy; Tx, treatment.

school/work domain (Table 2). HRQoL in the school/work domain was significantly lower in both NL and UK survivors compared with the weighted reference for all ages. This was also seen in the NL survivors  $\geq 18$  years and in the group of UK survivors 8 to 17 years, but not in other substrata. Effect sizes were moderate to large ( $d = 0.58$  to  $d = 0.88$ ). UK survivors also showed significantly lower HRQoL in the psychosocial health domain compared with the weighted reference, with moderate effect size ( $d = 0.55$ ).

**TABLE 2** HRQOL (PedsQL) of HNRMS survivors

|                     | Netherlands |      |      | NL reference      | NL cohort vs reference |                | United Kingdom |      |      | UK reference       | UK cohort vs reference |                |
|---------------------|-------------|------|------|-------------------|------------------------|----------------|----------------|------|------|--------------------|------------------------|----------------|
|                     | n           | Mean | SD   | Mean <sup>a</sup> | Effect size            | p <sup>b</sup> | N              | Mean | SD   | Mean               | Effect size            | p <sup>b</sup> |
| 8–17 years          | 16          |      |      |                   |                        |                | 17             |      |      |                    |                        |                |
| Total score         |             | 80.3 | 13.5 | 82.15             | −0.21                  | 0.60           |                | 73.1 | 21.9 | 82.65              | −0.73                  | 0.09           |
| Physical            |             | 88.3 | 13.7 | 85.39             | 0.31                   | 0.41           |                | 76.2 | 28.8 | 86.08 <sup>c</sup> | −0.70                  | 0.18           |
| Emotional           |             | 70.3 | 17.8 | 76.78             | −0.46                  | 0.17           |                | 74.5 | 22.4 | 78.10              | −0.20                  | 0.52           |
| Social              |             | 87.4 | 14.0 | 87.65             | −0.02                  | 0.95           |                | 77.4 | 20.4 | 86.85 <sup>c</sup> | −0.56                  | 0.07           |
| School/work         |             | 70.6 | 19.4 | 76.87             | −0.49                  | 0.22           |                | 62.4 | 23.7 | 77.29 <sup>c</sup> | −0.88                  | 0.02           |
| Psychosocial health |             | 76.1 | 15.4 | 80.42             | −0.42                  | 0.27           |                | 71.4 | 20.0 | 80.32              | −0.64                  | 0.08           |
| 18+ years           | 20          |      |      |                   |                        |                | 11             |      |      |                    |                        |                |
| Total score         |             | 82.3 | 12.1 | 84.81             | −0.20                  | 0.36           |                | 82.5 | 13.5 | 85.73 <sup>d</sup> | −0.25                  | 0.45           |
| Physical            |             | 86.6 | 17.3 | 88.28             | −0.11                  | 0.66           |                | 88.6 | 12.7 | 89.49 <sup>d</sup> | −0.06                  | 0.83           |
| Emotional           |             | 79.5 | 15.0 | 78.69             | 0.05                   | 0.81           |                | 71.8 | 18.6 | 80.18 <sup>d</sup> | −0.48                  | 0.17           |
| Social              |             | 88.0 | 13.4 | 87.6              | 0.03                   | 0.90           |                | 87.3 | 11.5 | 88.09 <sup>d</sup> | −0.06                  | 0.82           |
| School/work         |             | 72.5 | 15.0 | 82.57             | −0.58                  | 0.007          |                | 78.9 | 19.3 | 82.87 <sup>d</sup> | −0.26                  | 0.55           |
| Psychosocial health |             | 80.0 | 11.2 | 82.95             | −0.22                  | 0.25           |                | 78.9 | 15.2 | 83.71 <sup>d</sup> | −0.35                  | 0.32           |
| All ages            | 36          |      |      |                   |                        |                | 28             |      |      |                    |                        |                |
| Total score         |             | 81.4 | 12.6 | 83.63             | −0.20                  | 0.30           |                | 76.8 | 19.4 | 83.86              | −0.54                  | 0.06           |
| Physical            |             | 87.3 | 15.6 | 86.86             | 0.04                   | 0.86           |                | 81.1 | 12.7 | 87.42 <sup>c</sup> | −0.45                  | 0.18           |
| Emotional           |             | 75.4 | 16.7 | 77.70             | −0.14                  | 0.42           |                | 73.4 | 18.6 | 78.92              | −0.31                  | 0.17           |
| Social              |             | 87.7 | 13.5 | 87.48             | 0.02                   | 0.91           |                | 81.3 | 11.5 | 87.34 <sup>c</sup> | −0.37                  | 0.08           |
| School/work         |             | 71.7 | 16.9 | 80.27             | −0.58                  | 0.004          |                | 68.1 | 19.3 | 79.48 <sup>c</sup> | −0.70                  | 0.02           |
| Psychosocial health |             | 78.2 | 13.2 | 81.83             | −0.29                  | 0.11           |                | 74.3 | 15.2 | 81.97              | −0.55                  | 0.04           |

Pediatric Quality of Life Inventory (PedsQL) scale scores range 0–100, with higher scores indicating better health-related quality of life (HRQoL).

<sup>a</sup>Country-specific weighted reference scores, adjusted for sex and age.

<sup>b</sup>Based on one-sample t test.

<sup>c</sup>Not adjusted for sex because there was no sex effect in the reference group.

<sup>d</sup>No country-specific reference scores available; NL norm used for UK patients ≥18 years, adjusted for age and sex distribution.

#### 4.3 | Self-perception (KIDSCREEN)

Self-perception of HNRMS survivors did not differ from the weighted reference values (Supporting Information Table S2).

#### 4.4 | YQOL-FD

HNRMS survivors scored significantly lower on negative self-image and positive consequences compared with patients with mild facial deformities described by Patrick et al.<sup>23</sup> HNRMS survivors scored significantly higher on negative consequences (Table 3). Effect sizes ranged from moderate on positive consequences ( $d = 0.53$ ), to large ( $d = 0.91$ ) on negative self-image.

#### 4.5 | Satisfaction with appearances

Over 50% of NL and UK survivors negatively rated their appearances on three or more items. Over one-third of survivors in the NL and the UK scored negative on the items “noticeable to others” and/or “get on with others” (Table 4). Furthermore, over one-third of the UK survivors scored negative on the items “good looking,” “overall appearance,” and

“teeth,” whereas one-third of the NL survivors scored negative on the item “face.”

#### 4.6 | Association between adverse events and psychosocial well-being

Adverse events were previously described by Schoot et al.<sup>6</sup> In summary, over half of NL and UK survivors experienced any grade 3/4 adverse event and more than five adverse events of any grade. This was also reflected in high burden scores (Supporting Information Figures S1 and S2). Most common adverse events were musculoskeletal deformities of the face in NL and UK survivors, followed by fibrosis and scarring.

There were small negative correlations for CTC AE scores with HRQoL and self-perception (mainly not statistically significant). CTC AE scores (reflected in burden score and any grade 3/4 event) and YQOL-FD domains (except for positive consequences domain) showed medium to large, positive correlations (Table 5). Only small, negative (not significant) correlations between SWA scores and CTC AE scores were observed.

**TABLE 3** Quality-of-life facial differences (YQOL-FD) of HNRMS survivors

|                       | HNRMS          |      |      |           | Mild facial deformities <sup>a</sup> |      | Survivors vs mild facial differences |             |
|-----------------------|----------------|------|------|-----------|--------------------------------------|------|--------------------------------------|-------------|
|                       | n <sup>b</sup> | Mean | SD   | 95% CI    | Mean                                 | SD   | P <sup>c</sup>                       | Effect size |
| Negative self-image   |                |      |      |           |                                      |      |                                      |             |
| NL                    | 12             | 17.1 | 15.8 | 7.1–27.1  |                                      |      |                                      |             |
| UK                    | 11             | 12   | 17.4 | 0.3–23.6  |                                      |      |                                      |             |
| Total                 | 23             | 14.6 | 16.4 | 7.5–21.7  | 37.3                                 | 25.7 | <0.001                               | –0.91       |
| Positive consequences |                |      |      |           |                                      |      |                                      |             |
| NL                    | 12             | 55.2 | 25.7 | 38.8–71.5 |                                      |      |                                      |             |
| UK                    | 11             | 38.5 | 33.1 | 16.3–60.7 |                                      |      |                                      |             |
| Total                 | 23             | 47.2 | 30   | 34.2–60.2 | 60.7                                 | 24.9 | 0.042                                | –0.53       |
| Negative consequences |                |      |      |           |                                      |      |                                      |             |
| NL                    | 12             | 42.7 | 27.1 | 25.4–59.9 |                                      |      |                                      |             |
| UK                    | 11             | 23.5 | 31.4 | 2.3–44.6  |                                      |      |                                      |             |
| Total                 | 23             | 33.5 | 30.2 | 20.4–46.6 | 18.4                                 | 20.1 | 0.026                                | 0.72        |
| Stigma                |                |      |      |           |                                      |      |                                      |             |
| NL                    | 12             | 20.6 | 22.8 | 6.1–35.1  |                                      |      |                                      |             |
| UK                    | 11             | 19.1 | 29.5 | 0.0–38.9  |                                      |      |                                      |             |
| Total                 | 23             | 19.9 | 25.6 | 8.8–31.0  | 27.3                                 | 23.5 | 0.179                                | –0.31       |

YQOL-FD scale scores range 0–100, with higher scores on domain negative consequences, negative self-image, and stigma indicate lower quality of life, whereas higher scores on domain positive consequences indicate higher quality of life.

<sup>a</sup>Values obtained from patient group reported in Patrick et al (23) with self-rated mild facial deformities.

<sup>b</sup>Only patients 11–17 years.

<sup>c</sup>P value based on one-sample t test.

**TABLE 4** SWA of HNRMS survivors

|  | Netherlands |      |      |                       | United Kingdom |      |      |                       |
|--|-------------|------|------|-----------------------|----------------|------|------|-----------------------|
|  | n           | Mean | SD   | Negative <sup>a</sup> | n              | Mean | SD   | Negative <sup>a</sup> |
| Mean score (16 items)  | 35          | 7.44 | 1.35 | 14%                   | 29             | 7.48 | 1.61 | 24%                   |
| How do you feel about the way you look?                                      |             |      |      |                       |                |      |      |                       |
| How you face looks?  | 36          | 6.81 | 2.39 | 33%                   | 29             | 7.34 | 2.50 | 28%                   |
| The whole of you appearance?   | 36          | 7.44 | 1.75 | 14%                   | 29             | 7.41 | 2.38 | 35%                   |
| Side view/profile?   | 36          | 6.94 | 2.39 | 22%                   | 28             | 7.14 | 2.55 | 29%                   |
| How good looking do you think you are?                                       | 36          | 6.75 | 2.35 | 25%                   | 29             | 6.17 | 2.45 | 45%                   |
| How do you feel about these parts of your face?                              |             |      |      |                       |                |      |      |                       |
| Nose   | 36          | 7.69 | 2.32 | 14%                   | 29             | 8.00 | 2.17 | 17%                   |
| Lips   | 36          | 7.97 | 2.01 | 11%                   | 29             | 8.10 | 2.32 | 10%                   |
| Chin   | 36          | 7.61 | 2.62 | 17%                   | 29             | 8.17 | 1.97 | 14%                   |
| Teeth  | 36          | 7.03 | 2.24 | 22%                   | 29             | 6.21 | 2.88 | 41%                   |
| Cheeks   | 36          | 7.83 | 1.89 | 14%                   | 29             | 7.69 | 2.47 | 24%                   |
| Hair   | 36          | 8.17 | 2.01 | 11%                   | 29             | 8.83 | 1.65 | 3%                    |
| Ears   | 36          | 8.50 | 1.52 | 8%                    | 28             | 8.04 | 2.65 | 18%                   |
| Eyes   | 35          | 7.74 | 2.31 | 19%                   | 29             | 7.97 | 2.57 | 24%                   |
| How happy are you with your speech?  | 36          | 7.72 | 2.24 | 17%                   | 29             | 7.41 | 2.68 | 21%                   |
| How happy are you with your hearing?   | 36          | 8.22 | 2.21 | 14%                   | 29             | 8.14 | 2.17 | 10%                   |
| Overall how noticeable do you feel your face is to other people?             | 36          | 5.94 | 2.96 | 44%                   | 25             | 6.56 | 3.42 | 36%                   |
| Does the way you look make a difference to how you get on with other people? | 36          | 6.81 | 2.03 | 36%                   | 25             | 6.48 | 2.87 | 52%                   |

SWA scale scores range 0–10.

<sup>a</sup>Scores of  $\leq 5$  were considered negative.



**TABLE 5** Correlations of physician-assessed adverse effects (CTC AE outcome measures) with psychosocial outcomes

|                                       | $\geq 5$ AEs |          | Any grade 3/4 |              | Burden score <sup>a</sup> |              |
|---------------------------------------|--------------|----------|---------------|--------------|---------------------------|--------------|
|                                       | $r^b$        | <i>P</i> | $r^b$         | <i>P</i>     | $r^b$                     | <i>P</i>     |
| FD-negative self-image <sup>c</sup>   | 0.073        | 0.740    | <b>0.553</b>  | <b>0.006</b> | <b>0.531</b>              | <b>0.009</b> |
| FD-positive consequences <sup>c</sup> | -0.302       | 0.162    | 0.403         | 0.057        | 0.300                     | 0.165        |
| FD-negative consequences <sup>c</sup> | 0.007        | 0.973    | <b>0.463</b>  | <b>0.026</b> | <b>0.434</b>              | <b>0.038</b> |
| FD-stigma <sup>c</sup>                | 0.066        | 0.764    | <b>0.476</b>  | <b>0.022</b> | <b>0.465</b>              | <b>0.025</b> |
| SWA (mean score)                      | -0.127       | 0.318    | -0.223        | 0.076        | -0.231                    | 0.066        |
| PedsQL total                          | -0.155       | 0.222    | -0.156        | 0.218        | <b>-0.270</b>             | <b>0.031</b> |
| PedsQL physical                       | -0.227       | 0.071    | -0.182        | 0.151        | <b>-0.277</b>             | <b>0.027</b> |
| PedsQL emotional                      | -0.034       | 0.792    | -0.009        | 0.941        | -0.193                    | 0.126        |
| PedsQL social                         | -0.209       | 0.098    | -0.179        | 0.157        | <b>-0.284</b>             | <b>0.023</b> |
| PedsQL school/work                    | -0.015       | 0.906    | -0.147        | 0.254        | -0.149                    | 0.247        |
| PedsQL psychosocial                   | -0.090       | 0.482    | -0.122        | 0.337        | -0.233                    | 0.064        |
| Kidscreen self-perception             | 0.060        | 0.646    | 0.016         | 0.903        | 0.083                     | 0.520        |

In bold *P* value < 0.05.

<sup>a</sup>Burden score adapted from Geenen et al, combining number and severity of AE (24).

<sup>b</sup>Pearson correlation coefficient.

<sup>c</sup>YQOL-FD domains only for patients 11–17 years.

Abbreviations: AE, adverse effects; CTC, Common Terminology Criteria; FD, subscale of Youth Quality of Life Instrument–Facial Differences Module; HRQOL, health-related quality of life; PedsQL, Pediatric Quality of Life Inventory; SWA, satisfaction with appearance.

## 5 | DISCUSSION

In this cross-sectional study, we assessed psychosocial well-being specifically in a cohort of HNRMS survivors. These survivors were evaluated by a standardized protocol at a multidisciplinary outpatient clinic with a median follow-up of >10 years. This study, therefore, provides important insights into the psychosocial well-being of long-term HNRMS survivors and its association with adverse events.

In general, HRQoL and self-perception in HNRMS survivors was comparable to reference groups despite the high prevalence of (musculoskeletal) adverse events. However, survivors did report disease-specific consequences, which emphasize the need for systematic monitoring of psychosocial well-being.

Other studies in childhood cancer survivors (mainly tumors other than HNRMS) also found HRQoL to be comparable to reference values except for specific subgroups such as central nervous system tumor survivors, bone tumor survivors, and survivors who had cranial radiotherapy.<sup>8–11,26,27</sup>

In our cohort, HNRMS survivors showed impaired scores on school/work functioning, which was not shown in previous studies in other groups of childhood cancer survivors, except for survivors of central nervous system tumors.<sup>28–31</sup> We speculated that this finding may be related to specific adverse events experienced by these HNRMS survivors. Over 40% of the survivors had hearing loss, and many survivors suffered from eye conditions potentially causing difficulties to keep up at school/work. However, these conditions were not significantly correlated with school/work domain scores. The scores on school/work functioning could also be impaired because of radiotherapy treatment. Almost all included patients received radiotherapy (61/65 patients) and radiotherapy fields potentially involved parts of the brain. Although this effect might be less in patients treated

according to the AMORE principle, this could not be assessed because data on radiotherapy fields were not available.

The survivors also reported difficulties in more disease-specific domains. Musculoskeletal deformities were noticed in 63% of the patients and over one-third of all survivors considered their facial deformities very noticeable to other people and felt that their facial deformities negatively affected the way they get on with others. This was also reflected in the impact of facial differences on quality of life; HNRMS survivors experienced more negative consequences and fewer positive consequences due to their facial deformities, compared with a group of patients with mild facial deformities. Although the number of patients with musculoskeletal deformity was comparable between patients from the United Kingdom and the Netherlands, this did not reflect the severity of adverse events in both cohorts. Schoot et al previously showed that the severity of facial asymmetry (by clinical assessment) was larger in the UK survivors, compared with NL survivors.<sup>32</sup> Negative self-image, negative consequences, and stigma appeared to be associated with the severity of adverse events and the positive consequences appeared not to be associated with severity of adverse events. This result is in line with the study of Patrick et al, who found no relationship between severity of facial deformities and experienced positive consequences, whereas patients with more severe deformities reported significantly higher scores on negative consequences, negative self-image, and stigma.<sup>23</sup>

We observed important discrepancies in strength of correlation between the psychosocial outcomes and physician-assessed adverse events. Burden of adverse events showed only weak correlations with generic HRQoL and self-perception, whereas burden scores showed moderate/large correlation with experienced negative self-image, negative consequences, and stigma, underlining the necessity to use

disease-appropriate instruments to monitor psychosocial well-being in HNRMS survivors.

There are several limitations to this study. First, we have used disease-related questionnaires (YQOL-FD and SWA) based on the high incidence of facial deformities in this group of HNRMS survivors which were not previously used in childhood cancer survivors. Its applicability as well as our findings should therefore be confirmed in future studies. As for the YQOL-FD questionnaire, we have excluded the coping domain from our analyses because of low Cronbach's alpha. We recommend paying special attention to its reliability in future studies.

Second, this study included survivors treated over a period of 20 years in which treatment protocols have changed significantly and local treatment for patients in this cohort were different between countries. In a previous study, we showed that the local treatment strategy in the EKZ-AMC (i.e., AMORE treatment if feasible) resulted in fewer adverse events compared with standard external beam radiotherapy.<sup>6</sup> Because country-specific reference values were often not comparable or not available, we considered a comparison of psychosocial well-being between patients treated in EKZ-AMC with patients treated in the United Kingdom inappropriate.

Finally, although we have included survivors treated over a long period, total numbers of survivors in our analyses were limited, further complicated by the different age groups and related age-specific questionnaires. Nevertheless, we believe that this study offers important insights as this is the first study assessing psychosocial well-being in HNRMS survivors in depth.

In this study, we did not pay special attention to bullying. However, social interactions are strongly affected by facial appearances<sup>33</sup> and previous studies have shown that children (other than HNRMS survivors) with craniofacial conditions are at higher risk of being bullied compared with healthy peers.<sup>34</sup>

Based on the reported incidences and severity of adverse events in these long-term HNRMS survivors and reported dissatisfaction with appearances and HRQoL, we believe that monitoring of psychosocial well-being of HNRMS survivors should play an important part in standard aftercare. Merely administering generic HRQoL questionnaires is not enough to adequately measure whether long-term HNRMS survivors encounter problems in everyday life, which was also shown in adult head and neck cancer survivors.<sup>35,36</sup> We therefore recommend including disease-appropriate questionnaires in a systematic monitoring program, followed by tailored interventions such as psychosocial care or reconstructive surgery.

## ACKNOWLEDGMENTS

This work was supported by the KiKa foundation (Children Cancer-free), grant number 175. This foundation had no role in study design or interpretation of the data. We thank Daniele Hearst for the selection of the questionnaires.

## CONFLICTS OF INTEREST

Dr. J.C. Chisholm was supported by National Health Service funding to the National Institute for Health Research Biomedical Research

Center of the Royal Marsden Hospital. Dr. M.N. Gaze is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Dr. C.M. Ronckers is supported by a personal grant for Jr Group Leaders from the Dutch Cancer Society.

## ORCID

Bas Vaarwerk  <http://orcid.org/0000-0003-1336-0112>

Reineke A. Schoot  <http://orcid.org/0000-0002-8838-981X>

Heleen Maurice-Stam  <http://orcid.org/0000-0002-2055-3230>

Mark N. Gaze  <http://orcid.org/0000-0002-8344-7902>

Raquel Davila Fajardo  <http://orcid.org/0000-0002-4729-825X>

Julia C. Chisholm  <http://orcid.org/0000-0003-3479-7997>

## REFERENCES

1. Kaatsch P. Epidemiology of childhood cancer. *Cancer treatment reviews*. 2010;36:277–285.
2. Oberlin O, Rey A, Sanchez de Toledo J, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. *J Clin Oncol*. 2012;30:2457–2465.
3. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. *J Clin Oncol*. 2001;19:3091–3102.
4. Paulino AC, Simon JH, Zhen W, et al. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. *Int J Radiat Oncol Biol Phys*. 2000;48:1489–1495.
5. Lockney NA, Friedman DN, Wexler LH, et al. Late toxicities of intensity-modulated radiation therapy for head and neck rhabdomyosarcoma. *Pediatr Blood Cancer*. 2016;63:1608–1614.
6. Schoot RA, Slater O, Ronckers CM, et al. Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment. *Eur J Cancer*. 2015;51:1424–1434.
7. Clement SC, Schoot RA, Slater O, et al. Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma. *Eur J Cancer*. 2016;54:1–10.
8. Wengenroth L, Gianinazzi ME, Rueegg CS, et al. Health-related quality of life in young survivors of childhood cancer. *Qual Life Res*. 2015;24:2151–2161.
9. Zebrack BJ, Zevon MA, Turk N, et al. Psychological distress in long-term survivors of solid tumors diagnosed in childhood: a report from the childhood cancer survivor study. *Pediatr Blood Cancer*. 2007;49:47–51.
10. Zeltzer LK, Lu Q, Leisenring W, et al. Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: a report from the childhood cancer survivor study. *Cancer Epidemiol Biomarkers Prev*. 2008;17:435–446.
11. Zeltzer LK, Recklitis C, Buchbinder D, et al. Psychological status in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. *J Clin Oncol*. 2009;27:2396–2404.
12. Kinahan KE, Sharp LK, Seidel K, et al. Scarring, disfigurement, and quality of life in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *J Clin Oncol*. 2012;30:2466–2474.



13. Topolski TD, Edwards TC, Patrick DL. Quality of life: how do adolescents with facial differences compare with other adolescents? *Cleft Palate Craniofac J*. 2005;42:25–32.
14. Masnari O, Schiestl C, Rossler J, et al. Stigmatization predicts psychological adjustment and quality of life in children and adolescents with a facial difference. *J Pediatr Psychol*. 2013;38:162–172.
15. Buwalda J, Schouwenburg PF, Blank LE, et al. A novel local treatment strategy for advanced stage head and neck rhabdomyosarcomas in children: results of the AMORE protocol. *Eur J Cancer*. 2003;39:1594–1602.
16. Buwalda J, Blank LE, Schouwenburg PF, et al. The AMORE protocol as salvage treatment for non-orbital head and neck rhabdomyosarcoma in children. *Eur J Surg Oncol*. 2004;30:884–892.
17. Schoot RA, Theunissen EA, Slater O, et al. Hearing loss in survivors of childhood head and neck rhabdomyosarcoma: a long-term follow-up study. *Clin Otolaryngol*. 2016;41:276–283.
18. Varni JW, Burwinkle TM, Seid M, et al. The PedsQL (TM) 4.0 as a pediatric population health measure: feasibility, reliability, and validity. *Ambulatory Pediatrics*. 2003;3:329–341.
19. Engelen V, Haentjens MM, Detmar SB, et al. Health related quality of life of Dutch children: psychometric properties of the PedsQL in the Netherlands. *BMC Pediatr*. 2009;9:68.
20. Upton P, Eiser C, Cheung I, et al. Measurement properties of the UK-English version of the Pediatric Quality of Life Inventory 4.0 (PedsQL) generic core scales. *Health Qual Life Outcomes*. 2005;3:22.
21. Limperg PF, Haverman L, van Oers HA, et al. Health related quality of life in Dutch young adults: psychometric properties of the PedsQL generic core scales young adult version. *Health Qual Life Outcomes*. 2014;12:9.
22. Ravens-Sieberer U, Gosch A, Rajmil L, et al. The KIDSCREEN-52 quality of life measure for children and adolescents: psychometric results from a cross-cultural survey in 13 European countries. *Value Health*. 2008;11:645–658.
23. Patrick DL, Topolski TD, Edwards TC, et al. Measuring the quality of life of youth with facial differences. *Cleft Palate Craniofac J*. 2007;44:538–547.
24. Geenen MM, Cardous-Ubbink MC, Kremer LC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. *JAMA*. 2007;297:2705–2715.
25. Cohen JW. *Statistical Power Analysis for the Behavioral Sciences*. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
26. Speechley KN, Barrera M, Shaw AK, et al. Health-related quality of life among child and adolescent survivors of childhood cancer. *J Clin Oncol*. 2006;24:2536–2543.
27. Stokke J, Sung L, Gupta A, et al. Systematic review and meta-analysis of objective and subjective quality of life among pediatric, adolescent, and young adult bone tumor survivors. *Pediatr Blood Cancer*. 2015;62:1616–1629.
28. Meeske KA, Patel SK, Palmer SN, et al. Factors associated with health-related quality of life in pediatric cancer survivors. *Pediatr Blood Cancer*. 2007;49:298–305.
29. Ryerson AB, Wasilewski-Masker K, Border WL, et al. Pediatric quality of life in long-term survivors of childhood cancer treated with anthracyclines. *Pediatric Blood & Cancer*. 2016;63:2205–2211.
30. Eiser C, Vance YH, Horne B, et al. The value of the PedsQLTM in assessing quality of life in survivors of childhood cancer. *Child Care Health Dev*. 2003;29:95–102.
31. Meeske K, Katz ER, Palmer SN, et al. Parent proxy-reported health-related quality of life and fatigue in pediatric patients diagnosed with brain tumors and acute lymphoblastic leukemia. *Cancer*. 2004;101:2116–2125.
32. Schoot RA, Hol MLF, Merks JHM, et al. Facial asymmetry in head and neck rhabdomyosarcoma survivors. *Pediatr Blood Cancer*. 2017;64.
33. Langlois JH, Kalakanis L, Rubenstein AJ, et al. Maxims or myths of beauty? A meta-analytic and theoretical review. *Psychol Bull*. 2000;126:390–423.
34. Pinquart M. Systematic review: bullying involvement of children with and without chronic physical illness and/or physical/sensory disability—a meta-analytic comparison with healthy/nondisabled peers. *J Pediatr Psychol*. 2017;42:245–259.
35. Hammerlid E, Taft C. Health-related quality of life in long-term head and neck cancer survivors: a comparison with general population norms. *Br J Cancer*. 2001;84:149–156.
36. So WK, Chan RJ, Chan DN, et al. Quality-of-life among head and neck cancer survivors at one year after treatment—a systematic review. *Eur J Cancer*. 2012;48:2391–2408.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Vaarwerk B, Schoot RA, Maurice-Stam H, et al. Psychosocial well-being of long-term survivors of pediatric head–neck rhabdomyosarcoma. *Pediatr Blood Cancer*. 2019;66:e27498. <https://doi.org/10.1002/pbc.27498>